Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS occurs across mucosal surfaces or by direct inoculation.
Objective: The objective of this study was to consider chemically diverse scaffold sets of HIV-1 Reverse Transcriptase Inhibitors (HIV-1 RTI) subjected to ideal oriented QSAR with large descriptor space.
Method: We generated a four-parameter QSAR model based on 111 data points, which provided an optimum prediction of HIV-1 RTI for overall 367 experimentally measured compounds.
Results: The robustness of the model is demonstrated by its statistical validation (Ntraining = 111, R2 = 0.85, Q2lmo = 0.84) and by the prediction of HIV-1 inhibition activity for experimentally measured compounds.
Conclusion: Finally, 5 novel hit compounds were designed in silico by using a virtual screening approach. The new hits met all the pharmacophore constraints and predicted pIC50 values within the binding ability of HIV-1 RT protein targets.
Keywords: Global QSAR, applicability domain, diverse scaffolds, field points, scaffold hopping.
Graphical Abstract
Medicinal Chemistry
Title:Robust Modeling and Scaffold Hopping: Case Study Based on HIV Reverse Transcriptase Inhibitors Type-1 Data
Volume: 12 Issue: 6
Author(s): Girinath G. Pillai, Laznier Mederos, Chandramukhi S. Panda, Amber Gronski, Peeter Burk, Charles D. Hall, Alan R. Katritzky, Kaido Tämm and Mati Karelson
Affiliation:
Keywords: Global QSAR, applicability domain, diverse scaffolds, field points, scaffold hopping.
Abstract: Background: Human immunodeficiency virus type 1 (HIV-1) is the causative agent of AIDS occurs across mucosal surfaces or by direct inoculation.
Objective: The objective of this study was to consider chemically diverse scaffold sets of HIV-1 Reverse Transcriptase Inhibitors (HIV-1 RTI) subjected to ideal oriented QSAR with large descriptor space.
Method: We generated a four-parameter QSAR model based on 111 data points, which provided an optimum prediction of HIV-1 RTI for overall 367 experimentally measured compounds.
Results: The robustness of the model is demonstrated by its statistical validation (Ntraining = 111, R2 = 0.85, Q2lmo = 0.84) and by the prediction of HIV-1 inhibition activity for experimentally measured compounds.
Conclusion: Finally, 5 novel hit compounds were designed in silico by using a virtual screening approach. The new hits met all the pharmacophore constraints and predicted pIC50 values within the binding ability of HIV-1 RT protein targets.
Export Options
About this article
Cite this article as:
Pillai G. Girinath, Mederos Laznier, Panda S. Chandramukhi, Gronski Amber, Burk Peeter, Hall D. Charles, Katritzky R. Alan, Tämm Kaido and Karelson Mati, Robust Modeling and Scaffold Hopping: Case Study Based on HIV Reverse Transcriptase Inhibitors Type-1 Data, Medicinal Chemistry 2016; 12 (6) . https://dx.doi.org/10.2174/1573406411666151005110141
DOI https://dx.doi.org/10.2174/1573406411666151005110141 |
Print ISSN 1573-4064 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6638 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Nanotechnology Advancements in the Diagnosis and Prevention of COVID-19: Past and Future
Coronaviruses Death from Alcohol Consumption During the Outbreak of COVID-19
Current Psychiatry Research and Reviews Single Amino Acid Repeats Connect Viruses to Neurodegeneration
Current Drug Discovery Technologies Recent Developments on Coronavirus Main Protease/3C Like Protease Inhibitors
Recent Patents on Anti-Infective Drug Discovery Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation
Combinatorial Chemistry & High Throughput Screening Updates on the Production of Therapeutic Antibodies Using Human Hybridoma Technique
Current Pharmaceutical Design Intercorrelation of Major DNA/RNA Sequence Descriptors - A Preliminary Study
Current Computer-Aided Drug Design In Vitro Data of Current Therapies for SARS-CoV-2
Current Medicinal Chemistry Withdrawal Notice: Identification of the Interaction between Angiotensin-converting Enzyme Residues and Severe Acute Respiratory Syndrome Coronavirus 2
Current Pharmaceutical Design Molecular Recognition of Human Angiotensin-Coverting Enzyme I (hACE I) and Different Inhibitors
Current Topics in Medicinal Chemistry Oxytocin as a Potential Adjuvant Against COVID-19 Infection
Endocrine, Metabolic & Immune Disorders - Drug Targets Nanomaterial: A Sustainable Way to Fight Against COVID-19
Coronaviruses Prevalence of COVID-19-like Symptoms among People Living with HIV, and Using Antiretroviral Therapy for Prevention and Treatment
Current HIV Research COVID-19: Update on Pathogenesis and Treatment Strategies
Current Immunology Reviews (Discontinued) The Bananins: New Anticorona-RNA-Viral Agents with Unique Structural Signature
Anti-Infective Agents in Medicinal Chemistry Current Landscape of Natural Products against Coronaviruses: Perspectives in COVID-19 Treatment and Anti-viral Mechanism
Current Pharmaceutical Design COVID-19 Severity: Lung-Heart Interplay
Current Cardiology Reviews Epidemiological Characteristics of 64 Covid-19 Patients in Errachidia Province (Darâa-Tafilalet region), Morocco: A Retrospective Analysis
Reviews on Recent Clinical Trials Proteomic and Bioinformatics Tools to Understand Virulence Mechanisms in Staphylococcus aureus
Current Proteomics Advances of Inorganic Materials in the Detection and Therapeutic Uses against Coronaviruses
Current Medicinal Chemistry